Every 10-Q that AETHLON MEDICAL INC (AEMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AEMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AEMD filings page.
Aethlon Medical, Inc. reported another quarter as a clinical-stage company with no revenue, focused on developing its Hemopurifier immunotherapeutic device for oncology and life‑threatening viral infections. A Phase 1 oncology trial in Australia is ongoing at three sites, and Cohort 3 has begun enrollment.
For the three months ended June 30, 2026, operating expenses were $1.6 million, down from $1.8 million a year earlier, and the net loss narrowed to $1.55 million from $1.76 million. Research and development expenses were $549,000, reflecting continued investment in the Hemopurifier program.
At June 30, 2026, cash and cash equivalents were $4.93 million, total assets $6.24 million, and all liabilities were current at $1.04 million, resulting in stockholders’ equity of $5.20 million. The company raised approximately $1.9 million in gross proceeds via its at‑the‑market equity program during the quarter and subsequently completed a registered offering of about $4.0 million, plus a 1‑for‑5 reverse stock split effective July 31, 2026. Management states that existing cash, together with recent financings, is expected to fund planned operations for at least twelve months, though additional capital will likely be required to advance development beyond that period.
Aethlon Medical reported a quarterly net loss of $2.0 million for the three months ended December 31, 2025, slightly wider than a year earlier, while the nine‑month net loss improved to $5.3 million from $7.1 million. Operating expenses fell over the nine‑month period as payroll, general and administrative costs, and professional fees declined.
Cash, cash equivalents and restricted cash rose to $7.1 million, helped by equity financings and warrant exercises, but management states this cash is not sufficient to fund operations for at least twelve months, creating substantial doubt about the company’s ability to continue as a going concern. To address this, Aethlon completed a December 2025 private placement of pre‑funded and common warrants with gross proceeds of about $3.3 million and executed a warrant inducement that generated additional cash.
Clinically, the company is advancing its Hemopurifier device, designated by the FDA as a Breakthrough Device for certain cancers and life‑threatening viruses. The first oncology cohort in an Australian solid‑tumor trial (three patients) showed a favorable safety profile with no serious device‑related events, and enrollment has begun in a second cohort where patients receive two treatments. A planned Indian oncology trial was cancelled to conserve resources. Preclinical studies, released as non‑peer‑reviewed preprints, showed high removal of disease‑related extracellular vesicles, supporting future research directions but not yet clinical outcomes.
Aethlon Medical filed its quarterly report and detailed a smaller loss alongside a tight cash position and a going concern warning. The company reported a net loss of $1.49M for the quarter, with operating expenses of $1.51M, down 48% year over year. Cash and cash equivalents were $5.85M at September 30, 2025.
A registered direct offering closed in early September generated net proceeds of $3.74M. The share count increased to 761,318 outstanding as of November 10, 2025 following the offering and two reverse stock splits (1‑for‑8 in June and 1‑for‑10 in October). Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital.
Operationally, the phase 1 oncology trial in Australia treated three participants in Cohort 1; the DSMB raised no safety concerns and Cohort 2 enrollment is open. The quarter included an Australian R&D tax incentive of about $218,000 recognized as an expense reduction. The company regained Nasdaq minimum bid compliance after the October reverse split.
Aethlon Medical, Inc. (AEMD) reported a quarterly net loss of $1.76 million for the three months ended June 30, 2025, an improvement from $2.57 million a year earlier driven by lower payroll and professional fees. Revenue remained $0; operating expenses declined to $1.79 million from $2.62 million as headcount-related costs, severance and certain consulting fees decreased. Basic and diluted loss per share was ($0.85) versus ($2.76) in the prior year on a larger weighted-average share base of 2,076,416 shares.
Balance sheet highlights: cash and cash equivalents were $3.77 million, total assets $5.31 million, total liabilities $1.88 million, and stockholders' equity $3.42 million. Working capital fell to $2.42 million from $4.05 million at March 31, 2025. Management discloses substantial doubt about the company's ability to continue as a going concern and expects existing cash to be insufficient to fund operations for at least twelve months without additional financing.
Clinical and operational updates stated explicitly: the Hemopurifier phase 1 oncology trial is active at three Australian sites, three participants were treated in cohort 1 with no DSMB safety concerns, cohort 2 enrollment is open, the planned India trial (CDSCO-approved July 7, 2025) was cancelled to conserve resources, and a preprint reported >98% removal of platelet-derived EVs in an ex-vivo study. The company effected a 1-for-8 reverse stock split effective June 9, 2025 and maintains an open IDE for viral indications.